Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

NCT04838041 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Chronic Phase Chronic Myelogenous Leukemia

Interventions

DRUG: Asciminib 40 MG
DRUG: Asciminib 40 MG Twice Daily
DRUG: Asciminib 80 MG daily
DRUG: Imatinib
DRUG: Nilotinib
DRUG: Dasatinib

Sponsor

Medical College of Wisconsin

Collaborators

[object Object]